Discussion
tumor
TUMOR
Targeting immunomodulatory pathways beyond PD-1/PD-L1 is an emerging field in oncology. As LAG-3, TIM3, BTLA, and TIGIT belong to the co-inhibitory receptors, which are known to impair anti-tumor immunity [Beyond safety, we aim to detect an activity signal of our combination. Secondary analyses will help to sustain emerging data that suggest the critical role of cytokine production in the tumor microenvironment [